X-ray Dose Reduction Study for Endovascular Interventional Radiology

• ClinicalTrials.gov Identifier: NCT01599741
• Recruitment Status: Completed
• First Posted: May 16, 2012
• Results First Posted: March 5, 2014
• Last Update Posted: March 8, 2022
• Sponsor: Philips Clinical & Medical Affairs Global
• Information provided by (Responsible Party): Philips Clinical & Medical Affairs Global

Study Description

Brief Summary:

ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. This is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. Furthermore, smaller focal spot sizes, shorter pulses and the introduction of automatic real-time motion compensation in subtraction imaging are used, which are known to positively influence image quality . The final effect on the clinical image quality in peripheral angiography is investigated in this study.

Condition or disease	Intervention/treatment	Phase
Cardiovascular Disease	Radiation: Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.; Radiation: Normal dose DSA with conventional X-ray imaging technology	Not Applicable

Detailed Description:

X-ray dose and image quality are related by laws of physics. Low dose and high image quality cannot be achieved at the same time. However, image processing algorithms can help an x-ray system to acquire images with lower dose without influencing image quality or achieving higher image quality with equal dose. The primary aim of this study is to verify if the diagnostic image quality is equal or better when using a significant reduction in X-ray dose for endovascular digital subtraction angiography in combination with a novel imaging technology compared to using normal dose with conventional image technology.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 51 participants
• Allocation: Non-Randomized
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Clinical Validation and Evaluation of X-ray Image Processing for Endovascular Digital Subtraction Angiography and Intervention
• Study Start Date: June 2012
• Actual Primary Completion Date: May 2013
• Actual Study Completion Date: May 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: ClarityIQ; Low-dose DSA (83% reducation compared to normal dose) with novel X-ray imaging technology.	Radiation: Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.; Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.; Other Name: ClarityIQ
Active Comparator: AlluraXper; Normal dose DSA with conventional X-ray imaging technology.	Radiation: Normal dose DSA with conventional X-ray imaging technology; Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.; Other Name: AlluraXper

Outcome Measures

Primary Outcome Measures :

1. Image Quality [ Time Frame: 1 Day ]
   Overall proportion where diagnostic image quality of ClarityIQ is scored equal or better compared to AlluraXper by the blinded reviewers. Reading is performed by simultaneous visual comparison of image quality of AlluraXper and ClarityIQ by multiple blinded readers. All blinded readers have rated all side-by-side presented images. The images are presented in a random order and blinded to the reader. The hypothesis is that the overall proportion where diagnostic image quality of ClarityIQ is scored equal or better is ≥ than 0.80. Combined for all raters, the lower bound of the one-sided 95% CI (lower bound of the two-sided 90% CI) is used.

Secondary Outcome Measures :

1. Radiation Dose Measurements: Dose Area Product (DAP) [ Time Frame: Participants were followed for the duration of the procedure ]

   Percentage dose change of ClarityIQ vs. AlluraXper in DAP calculated by DAP/frame for DSA. Negative change means a reduction in dose for ClarityIQ vs. AlluraXper.

   DAP was measured during the ClarityIQ and AlluraXper runs during the procedure.

2. Radiation Dose Measurements: Air Kerma (AK) [ Time Frame: Participants were followed for the duration of the procedure ]

   Percentage dose change of ClarityIQ vs. AlluraXper in AK calculated by AK/frame for DSA. Negative change means a reduction in dose for ClarityIQ vs. AlluraXper.

   AK was measured during the ClarityIQ and AlluraXper runs during the procedure.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients older than 18 years of age undergoing digital subtraction angiography for diagnosis or treatment of iliac artery disease.

Exclusion Criteria:

• Patients not willing or unable to give consent to participate
• Patients already involved in a clinical trial
• Patients under the age of 18
• Pregnant or breastfeeding women
• Patients with kidney disease (eGFR < 60)

Contacts and Locations

Locations

Netherlands

St. Antonius Ziekenhuis

Nieuwegein, Netherlands, 3430 EM

Sponsors and Collaborators

Philips Clinical & Medical Affairs Global

Investigators

• Principal Investigator: Marco van Strijen, MD; St. Antonius Ziekenhuis

More Information

• Responsible Party: Philips Clinical & Medical Affairs Global
• ClinicalTrials.gov Identifier: NCT01599741
• Other Study ID Numbers: XCY607-100093
• First Posted: May 16, 2012
• Results First Posted: March 5, 2014
• Last Update Posted: March 8, 2022
• Last Verified: March 2022

Keywords provided by Philips Clinical & Medical Affairs Global:

X-rays; Endovascular angiography; Image processing

Additional relevant MeSH terms:

Cardiovascular Diseases